TranspoCART19 / Institute of Biomedical Research of Salamanca - LARVOL DELTA

CART-NEL: Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis (clinicaltrials.gov) - P1/2 | N=10 | Not yet recruiting | Sponsor: Instituto de Investigacin Sanitaria de la Fundacin Jimnez Daz

IO biomarker • New P1/2 trial • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

CART-NEL: Phase I-IIa, national, multicenter, clinical trial to evaluate the safety and preliminary efficacy of CAR-T CD19 therapy in patients with refractory lupus nephritis. (clinicaltrialsregister.eu) - P1/2 | N=10 | Not yet recruiting | Sponsor: Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

New P1/2 trial • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Transpocall19: Single-center phase I/IIa study with CART cells produced using the anti-CD19 transposon technique (TranspoCART19) for patients with CD19+ acute lymphoblastic leukemia resistant or refractory to treatment (clinicaltrialsregister.eu) - P1/2 | N=24 | Recruiting | Sponsor: Clinica Universidad De Navarra | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology